Human African Trypanosomiasis: Clinical Presentation and Immune Response

Research output: Contribution to journalArticle

71 Citations (Scopus)

Abstract

Human African trypanosomiasis or sleeping sickness is caused by infection with two subspecies of the tsetse-fly-vectored haemoflagellate parasite Trypanosoma brucei. Historically, epidemic sleeping sickness has caused massive loss of life, and related animal diseases have had a crucial impact on development in sub-Saharan Africa. After a period of moderately successful control during the mid-part of the 20th century, sleeping sickness incidence is currently rising, and control is hampered by a combination of factors, including civil unrest and the possible development of drug resistance by the parasites. The prevailing view is that the disease is invariably fatal without anti-trypanosomal drug treatment. However, there have also been intriguing reports of wide variations in disease severity as well as evidence of asymptomatic carriers of trypanosomes. These differences in the presentation of the disease will be discussed in the context of our knowledge of the immunology of trypanosomiasis. The impact of dysregulated inflammatory responses in both systemic and CNS pathology will be examined and the potential for host genotype variation in disease severity and control will be discussed.

Original languageEnglish
Pages (from-to)469-476
Number of pages7
JournalParasite Immunology
Volume26
DOIs
Publication statusPublished - 2004

Keywords

  • clinical presentation
  • Human African trypanosomiasis
  • immune response
  • Trypanosoma brucei
  • NECROSIS-FACTOR-ALPHA
  • VARIANT SURFACE GLYCOPROTEIN
  • CENTRAL-NERVOUS-SYSTEM
  • SLEEPING-SICKNESS PATIENTS
  • CLASSICAL MACROPHAGE ACTIVATION
  • BRUCEI-RHODESIENSE INFECTIONS
  • NITRIC-OXIDE PRODUCTION
  • T-CELL RESPONSES
  • ANTIGENIC VARIATION
  • COTE-DIVOIRE

Cite this

Human African Trypanosomiasis: Clinical Presentation and Immune Response. / Sternberg, Jeremy M.

In: Parasite Immunology, Vol. 26, 2004, p. 469-476.

Research output: Contribution to journalArticle

@article{bf689596008d4d0dbe98c1ded37bde70,
title = "Human African Trypanosomiasis: Clinical Presentation and Immune Response",
abstract = "Human African trypanosomiasis or sleeping sickness is caused by infection with two subspecies of the tsetse-fly-vectored haemoflagellate parasite Trypanosoma brucei. Historically, epidemic sleeping sickness has caused massive loss of life, and related animal diseases have had a crucial impact on development in sub-Saharan Africa. After a period of moderately successful control during the mid-part of the 20th century, sleeping sickness incidence is currently rising, and control is hampered by a combination of factors, including civil unrest and the possible development of drug resistance by the parasites. The prevailing view is that the disease is invariably fatal without anti-trypanosomal drug treatment. However, there have also been intriguing reports of wide variations in disease severity as well as evidence of asymptomatic carriers of trypanosomes. These differences in the presentation of the disease will be discussed in the context of our knowledge of the immunology of trypanosomiasis. The impact of dysregulated inflammatory responses in both systemic and CNS pathology will be examined and the potential for host genotype variation in disease severity and control will be discussed.",
keywords = "clinical presentation, Human African trypanosomiasis, immune response, Trypanosoma brucei, NECROSIS-FACTOR-ALPHA, VARIANT SURFACE GLYCOPROTEIN, CENTRAL-NERVOUS-SYSTEM, SLEEPING-SICKNESS PATIENTS, CLASSICAL MACROPHAGE ACTIVATION, BRUCEI-RHODESIENSE INFECTIONS, NITRIC-OXIDE PRODUCTION, T-CELL RESPONSES, ANTIGENIC VARIATION, COTE-DIVOIRE",
author = "Sternberg, {Jeremy M}",
year = "2004",
doi = "10.1111/j.0141-9838.2004.00731.x",
language = "English",
volume = "26",
pages = "469--476",
journal = "Parasite Immunology",
issn = "0141-9838",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Human African Trypanosomiasis: Clinical Presentation and Immune Response

AU - Sternberg, Jeremy M

PY - 2004

Y1 - 2004

N2 - Human African trypanosomiasis or sleeping sickness is caused by infection with two subspecies of the tsetse-fly-vectored haemoflagellate parasite Trypanosoma brucei. Historically, epidemic sleeping sickness has caused massive loss of life, and related animal diseases have had a crucial impact on development in sub-Saharan Africa. After a period of moderately successful control during the mid-part of the 20th century, sleeping sickness incidence is currently rising, and control is hampered by a combination of factors, including civil unrest and the possible development of drug resistance by the parasites. The prevailing view is that the disease is invariably fatal without anti-trypanosomal drug treatment. However, there have also been intriguing reports of wide variations in disease severity as well as evidence of asymptomatic carriers of trypanosomes. These differences in the presentation of the disease will be discussed in the context of our knowledge of the immunology of trypanosomiasis. The impact of dysregulated inflammatory responses in both systemic and CNS pathology will be examined and the potential for host genotype variation in disease severity and control will be discussed.

AB - Human African trypanosomiasis or sleeping sickness is caused by infection with two subspecies of the tsetse-fly-vectored haemoflagellate parasite Trypanosoma brucei. Historically, epidemic sleeping sickness has caused massive loss of life, and related animal diseases have had a crucial impact on development in sub-Saharan Africa. After a period of moderately successful control during the mid-part of the 20th century, sleeping sickness incidence is currently rising, and control is hampered by a combination of factors, including civil unrest and the possible development of drug resistance by the parasites. The prevailing view is that the disease is invariably fatal without anti-trypanosomal drug treatment. However, there have also been intriguing reports of wide variations in disease severity as well as evidence of asymptomatic carriers of trypanosomes. These differences in the presentation of the disease will be discussed in the context of our knowledge of the immunology of trypanosomiasis. The impact of dysregulated inflammatory responses in both systemic and CNS pathology will be examined and the potential for host genotype variation in disease severity and control will be discussed.

KW - clinical presentation

KW - Human African trypanosomiasis

KW - immune response

KW - Trypanosoma brucei

KW - NECROSIS-FACTOR-ALPHA

KW - VARIANT SURFACE GLYCOPROTEIN

KW - CENTRAL-NERVOUS-SYSTEM

KW - SLEEPING-SICKNESS PATIENTS

KW - CLASSICAL MACROPHAGE ACTIVATION

KW - BRUCEI-RHODESIENSE INFECTIONS

KW - NITRIC-OXIDE PRODUCTION

KW - T-CELL RESPONSES

KW - ANTIGENIC VARIATION

KW - COTE-DIVOIRE

U2 - 10.1111/j.0141-9838.2004.00731.x

DO - 10.1111/j.0141-9838.2004.00731.x

M3 - Article

VL - 26

SP - 469

EP - 476

JO - Parasite Immunology

JF - Parasite Immunology

SN - 0141-9838

ER -